Calamos Advisors
APEN

Calamos Advisors’s Apollo Endosurgery, Inc. APEN Stock Holding History

Calamos Advisors’s Portfolio APEN Stock Details APEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-112,502
Closed -$681K – 1241
2022
Q1 		$681K Sell
112,502
-16,062
-12% -$97.9K ﹤0.01% 1060
2021
Q4 		$1.08M Buy
+128,564
New +$1.12M ﹤0.01% 973

Other funds holding APEN

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Calamos Advisors's APEN Position: Q2 2022 in Review

Calamos Advisors sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2022, closing a stake of 112,502 shares — an estimated $681K sold.

Calamos Advisors first reported a position in APEN in Q4 2021 and held it in 2 quarters. The position peaked at $1.08M in Q4 2021. 63 funds tracked by Wall St. Rank hold APEN as of Q2 2022.

  • Calamos Advisors reported no remaining Apollo Endosurgery, Inc. position as of Q2 2022 after selling out during the quarter.
  • Calamos Advisors sold 112,502 Apollo Endosurgery, Inc. shares in Q2 2022, an estimated $681K.
  • Calamos Advisors first reported a position in Apollo Endosurgery, Inc. in Q4 2021 and held it in 2 quarters.
  • Calamos Advisors's Apollo Endosurgery, Inc. position peaked at $1.08M in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.